Study: NCT01993719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/day X 2 days intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/day X 2 days intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/day X 2 days intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/day X 2 days intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -5 to -3 (low-dose arm): 300 mg/m\^2 IV over 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Day 0: Cells will be infused intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Day 0: Cells will be infused intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Day 0: Cells will be infused intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Day 0: Cells will be infused intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Day 0: Cells will be infused intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 2 mg/kg intravenous (IV) on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).